OKYO Pharma’s Chairman Increases Stake with Recent Share Acquisition

The latest update is out from OKYO Pharma Limited Sponsored ADR ( (OKYO) ).

On November 21, 2025, OKYO Pharma Limited announced that Panetta Partners Limited, associated with Executive Chairman Gabriele Cerrone, acquired 82,018 ordinary shares of the company on NASDAQ, increasing his total holding to 10,464,695 shares. This acquisition signifies a strong vote of confidence from the leadership in the company’s future prospects, particularly as OKYO has recently completed a Phase 2 trial of urcosimod for treating neuropathic corneal pain, a condition lacking FDA-approved therapies.

The most recent analyst rating on (OKYO) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.

Spark’s Take on OKYO Stock

According to Spark, TipRanks’ AI Analyst, OKYO is a Underperform.

OKYO Pharma Limited’s stock is primarily affected by its significant financial challenges, including no revenue generation and negative equity. Technical analysis provides a neutral to slightly bearish outlook, while traditional valuation metrics are not applicable, reflecting typical biotech industry characteristics.

To see Spark’s full report on OKYO stock, click here.

More about OKYO Pharma Limited Sponsored ADR

OKYO Pharma Limited is a clinical stage biopharmaceutical company focused on developing innovative therapies for neuropathic corneal pain and dry eye disease. The company is advancing its lead product, urcosimod, a novel drug candidate designed to treat these ocular conditions, with its shares listed on the NASDAQ Capital Market.

Average Trading Volume: 122,815

Technical Sentiment Signal: Buy

Current Market Cap: $75.97M

See more insights into OKYO stock on TipRanks’ Stock Analysis page.